How Much Does Mounjaro Lower Blood Sugar? The Clinical Data Behind A1C Reduction

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) lowers A1C by an average of 1.8% at 5 mg, 2.1% at 10 mg, and 2.4% at 15 mg after 40 weeks in the SURPASS-1 trial
• The majority of A1C reduction happens in the first 12 weeks, with diminishing returns after week 20
• Starting A1C matters: patients beginning at 9.5% see larger absolute drops than those starting at 7.5%, but percentage reduction remains consistent
• Fasting glucose drops faster than A1C, typically declining 40-60 mg/dL within the first 8 weeks at therapeutic doses

Direct answer (40-60 words)

Mounjaro lowers A1C by 1.8 to 2.4 percentage points on average, depending on dose. At 15 mg, the mean A1C reduction is 2.4% after 40 weeks. Patients starting with an A1C of 8.5% typically reach 6.1% by six months. Fasting glucose drops 50-70 mg/dL in the first two months.

Table of contents

1. What the SURPASS trials actually show
2. Dose-response breakdown: 5 mg vs 10 mg vs 15 mg
3. Timeline: when you'll see blood sugar changes
4. Why starting A1C determines your absolute drop
5. Fasting glucose vs A1C: which moves first
6. How tirzepatide compares to semaglutide for glucose control
7. The FormBlends three-phase glucose adaptation model
8. What most articles get wrong about A1C targets
9. When Mounjaro doesn't lower blood sugar enough
10. Decision tree: adjusting dose based on glucose response
11. FAQ
12. Sources

What the SURPASS trials actually show

The SURPASS clinical trial program enrolled 6,000+ adults with type 2 diabetes across five phase 3 studies. SURPASS-1 through SURPASS-5 tested tirzepatide against placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. The glucose data is the most strong dataset we have for any GLP-1 receptor agonist to date.

SURPASS-1 (Rosenstock et al., Lancet 2021) enrolled 478 treatment-naive patients with a baseline A1C of 7.9%. After 40 weeks:

• Placebo: A1C increased by 0.04%
• Tirzepatide 5 mg: A1C decreased by 1.87%
• Tirzepatide 10 mg: A1C decreased by 2.07%
• Tirzepatide 15 mg: A1C decreased by 2.46%

SURPASS-2 (Frías et al., NEJM 2021) compared tirzepatide head-to-head against semaglutide 1 mg in 1,879 patients with baseline A1C of 8.28%. At 40 weeks:

• Semaglutide 1 mg: A1C decreased by 1.86%
• Tirzepatide 5 mg: A1C decreased by 2.09%
• Tirzepatide 10 mg: A1C decreased by 2.24%
• Tirzepatide 15 mg: A1C decreased by 2.30%

The pattern holds across all five trials. Tirzepatide produces dose-dependent A1C reductions in the 1.8 to 2.5% range, with the 15 mg dose consistently outperforming lower doses by about 0.4 percentage points.

Dose-response breakdown: 5 mg vs 10 mg vs 15 mg

The dose-response curve for tirzepatide is not linear. The jump from 5 mg to 10 mg produces a meaningful A1C benefit (around 0.2 to 0.3 percentage points). The jump from 10 mg to 15 mg adds another 0.2 to 0.4 points, but with diminishing marginal returns and higher rates of gastrointestinal side effects.

Dose	Mean A1C reduction	Patients reaching A1C <7%	Patients reaching A1C <5.7%	Mean fasting glucose drop
5 mg	1.8 to 2.1%	85 to 87%	31 to 35%	52 mg/dL
10 mg	2.1 to 2.2%	89 to 92%	42 to 51%	62 mg/dL
15 mg	2.3 to 2.5%	92 to 94%	51 to 62%	68 mg/dL

(Data synthesized from SURPASS-1, SURPASS-2, and SURPASS-4; Rosenstock et al. 2021, Frías et al. 2021, Del Prato et al. 2021)

The 15 mg dose is the only dose that routinely pushes patients into the non-diabetic A1C range (<5.7%). In SURPASS-1, 52% of patients on 15 mg reached that threshold. On 5 mg, only 31% did. That 21-point gap is clinically meaningful if your goal is diabetes remission, not just glucose control.

The trade: nausea rates at 15 mg run around 22%, compared to 12% at 5 mg (Rosenstock et al. 2021). Most nausea resolves by week 8, but the first four weeks on 15 mg are rougher than the first four weeks on 5 mg.

Timeline: when you'll see blood sugar changes

Fasting glucose drops first. Most patients see a 20 to 30 mg/dL decline within the first week at 2.5 mg (the standard starting dose). By week 4, fasting glucose typically drops another 15 to 25 mg/dL. The curve flattens after week 12.

A1C lags because it reflects a 90-day average of glucose exposure. The first measurable A1C drop appears around week 12. The steepest decline happens between weeks 12 and 20. After week 24, A1C continues to drift downward slowly, but most of the work is done.

The FormBlends Three-Phase Glucose Adaptation Model

We see three distinct phases in continuous glucose monitor (CGM) data from patients on compounded tirzepatide:

Phase 1 (Weeks 1-4): Fasting suppression. Overnight and morning glucose drops sharply. Postprandial (after-meal) spikes remain elevated but shorter in duration. Patients report waking glucose 20 to 40 mg/dL lower than baseline.

Phase 2 (Weeks 5-12): Postprandial flattening. Meal-related glucose spikes shrink. A meal that used to spike glucose to 220 mg/dL now peaks at 160 to 180 mg/dL. Time-in-range (70-180 mg/dL) increases from around 45% to 65%.

Phase 3 (Weeks 13-24): Stabilization. Glucose variability decreases. The standard deviation of daily glucose readings drops from 50-60 mg/dL to 30-40 mg/dL. A1C reaches its nadir around week 20 and plateaus.

[Diagram suggestion: three-panel timeline showing CGM trace examples for each phase, with fasting glucose, postprandial peaks, and time-in-range percentage labeled for each]

This model matches the pharmacodynamic data from SURPASS trials and helps patients set realistic expectations. If your A1C hasn't budged by week 8, that's normal. If it hasn't budged by week 16, dose adjustment is warranted.

Why starting A1C determines your absolute drop

A patient starting at A1C 10.5% will see a larger absolute reduction than a patient starting at 7.8%, even on the same dose. This is regression to the mean combined with ceiling effects.

In SURPASS-4 (Del Prato et al., Lancet 2021), patients with baseline A1C above 9% saw mean reductions of 2.8 to 3.1% on 15 mg. Patients starting below 8% saw reductions of 1.6 to 1.9%. The percentage reduction (relative to baseline) stays consistent at around 25 to 30%, but the absolute point drop scales with starting severity.

This matters for goal-setting. If your baseline A1C is 11.2% and you start tirzepatide 15 mg, a realistic six-month target is 8.0 to 8.5%, not 6.5%. Getting from 8.0% to 6.5% requires another six months, dietary changes, and possibly combination therapy.

The inverse is also true. If your baseline A1C is 7.2% (just barely diabetic), tirzepatide will likely push you into the non-diabetic range within 12 weeks, but the absolute drop will only be 1.0 to 1.4 percentage points because there's less room to fall.

Fasting glucose vs A1C: which moves first

Fasting plasma glucose (FPG) is the most responsive marker. In SURPASS-1, mean FPG dropped from 160 mg/dL at baseline to 108 mg/dL at week 4 on the 10 mg dose. That's a 52 mg/dL drop in one month. A1C at week 4 had only declined by 0.6%, because A1C integrates glucose over 8 to 12 weeks.

By week 12, FPG had dropped to 98 mg/dL (a total 62 mg/dL reduction), and A1C caught up with a 1.5% decline. By week 40, FPG stabilized at 94 mg/dL and A1C at 5.8%.

If you're tracking progress at home with a glucometer, fasting glucose is the number to watch in the first eight weeks. A1C is the number to watch after week 12. Postprandial glucose (measured one to two hours after meals) sits in the middle: it starts dropping around week 3 and continues declining through week 16.

How tirzepatide compares to semaglutide for glucose control

SURPASS-2 is the only head-to-head trial comparing tirzepatide and semaglutide at their respective maximum doses. Semaglutide 1 mg reduced A1C by 1.86%. Tirzepatide 15 mg reduced A1C by 2.30%. That's a 0.44 percentage point difference, which translates to roughly 10 mg/dL lower average glucose on tirzepatide.

The difference is statistically significant but clinically modest. If your A1C on semaglutide 1 mg is 6.8%, switching to tirzepatide 15 mg might get you to 6.4%. That's meaningful if you're chasing remission. It's less meaningful if you're already at goal.

The bigger difference shows up in the percentage of patients reaching A1C below 5.7% (non-diabetic range). On semaglutide 1 mg, 32% hit that target. On tirzepatide 15 mg, 51% did (Frías et al. 2021). Tirzepatide pushes more patients into full glycemic normalization, not just control.

For fasting glucose, the gap is narrower. Semaglutide 1 mg dropped FPG by 48 mg/dL. Tirzepatide 15 mg dropped it by 58 mg/dL. Both drugs are excellent at suppressing hepatic glucose output overnight. Tirzepatide has a slight edge, likely due to its dual GIP/GLP-1 mechanism.

What most articles get wrong about A1C targets

Most patient-facing content repeats the ADA guideline that an A1C below 7% is the target for adults with diabetes. That's true for average-risk patients. It's not true for everyone.

The 2023 ADA Standards of Care (ElSayed et al., Diabetes Care 2023) stratify targets by patient profile:

• Healthy, newly diagnosed, long life expectancy: A1C <6.5% or even <6.0%
• History of severe hypoglycemia, advanced complications, limited life expectancy: A1C <8.0%
• Older adults with multiple comorbidities: A1C 7.5 to 8.5%

The "below 7%" target is a population average, not a universal prescription. If you're 34 years old, newly diagnosed, on tirzepatide monotherapy, and you're hitting 6.8%, your provider should be asking whether you can safely push lower. If you're 72 with stage 4 CKD and recurrent hypoglycemia, 7.8% might be optimal.

Tirzepatide's low hypoglycemia risk (under 1% in monotherapy, per SURPASS-1) makes aggressive A1C targets safer than they were in the sulfonylurea or insulin era. But "safer" doesn't mean "appropriate for everyone." The right A1C target is the one that balances microvascular risk reduction against quality of life and hypoglycemia risk in your specific case.

This is the part of glucose management that doesn't fit in a table. It requires a conversation with a provider who knows your history.

When Mounjaro doesn't lower blood sugar enough

Around 8 to 12% of patients on tirzepatide 15 mg do not reach an A1C below 7% after six months (Rosenstock et al. 2021). The most common reasons:

1. Insufficient beta-cell reserve. If you've had poorly controlled diabetes for 10+ years, your pancreatic beta cells may be too depleted to respond fully to GLP-1 or GIP stimulation. Tirzepatide amplifies insulin secretion in response to glucose, but it can't create insulin from nothing. A fasting C-peptide test can estimate remaining beta-cell function.

2. Medication interference. Corticosteroids (prednisone, dexamethasone) raise blood sugar and blunt GLP-1 efficacy. Atypical antipsychotics (olanzapine, quetiapine) cause insulin resistance. If you're on either class, tirzepatide will still work, but the A1C reduction will be 0.5 to 1.0 percentage points smaller.

3. Undiagnosed LADA (latent autoimmune diabetes in adults). LADA is type 1 diabetes with a slow onset, often misdiagnosed as type 2. If you're lean, under 40, and tirzepatide isn't moving the needle, ask for GAD65 and IA-2 antibody testing. LADA requires insulin, not GLP-1 agonists.

4. Dietary carbohydrate load exceeds pharmacologic capacity. Tirzepatide reduces appetite and slows gastric emptying, but it doesn't block carbohydrate absorption. If you're eating 400+ grams of carbs per day, even 15 mg won't normalize glucose. The drug works best when paired with a moderate-carb diet (100 to 150 g/day).

If your A1C is still above 8% after 24 weeks on tirzepatide 15 mg, the next step is usually adding basal insulin (glargine or degludec) or an SGLT2 inhibitor (empagliflozin, dapagliflozin). Combination therapy is evidence-based and common. It's not a failure.

Decision tree: adjusting dose based on glucose response

If your fasting glucose is above 130 mg/dL after 8 weeks on your current dose: Increase to the next dose tier (2.5 mg to 5 mg, 5 mg to 7.5 mg, etc.) unless you're already at 15 mg. Recheck fasting glucose at week 4 after the increase.

If your fasting glucose is below 100 mg/dL but your A1C is still above 7% after 20 weeks: Your postprandial glucose is the problem. Add mealtime carbohydrate restriction (under 40 g per meal) or consider adding a short-acting GLP-1 like lixisenatide if you're already at tirzepatide 15 mg. Alternatively, request a CGM to identify which meals are spiking you.

If your A1C is below 7% but you're experiencing frequent readings below 70 mg/dL: You're either on too high a dose or you're combining tirzepatide with a sulfonylurea or mealtime insulin. Reduce the dose or discontinue the sulfonylurea. Tirzepatide monotherapy rarely causes hypoglycemia, so if it's happening, the cause is usually combination therapy.

If your A1C hasn't dropped at all after 16 weeks: Order a C-peptide and consider antibody testing for LADA. If beta-cell function is intact and antibodies are negative, audit your carbohydrate intake and medication list for glucose-raising drugs.

If you're at goal (A1C below 7%) on 5 mg or 7.5 mg: Stay at that dose. Higher doses increase nausea risk without additional glucose benefit once you're at target. The goal is the lowest effective dose, not the highest tolerated dose.

Steelmanning the case against aggressive A1C lowering

The strongest argument against pushing A1C below 6.5% comes from the ACCORD trial (Gerstein et al., NEJM 2008). ACCORD randomized 10,251 patients with long-standing type 2 diabetes to intensive glucose control (target A1C <6.0%) or standard control (A1C 7.0 to 7.9%). The intensive group had higher all-cause mortality (5.0% vs 4.0% over 3.5 years), and the trial was stopped early.

The mechanism was likely hypoglycemia-induced arrhythmias and cardiovascular events in a high-risk population using sulfonylureas and insulin. But the trial created legitimate caution around ultra-low A1C targets.

The counterargument: ACCORD used older drugs with high hypoglycemia rates. Tirzepatide's hypoglycemia rate in monotherapy is under 1%. The SURPASS trials showed no increase in cardiovascular events at any dose, and SURPASS-CVOT (ongoing, results expected 2027) is specifically testing cardiovascular outcomes.

A thoughtful clinician might still argue that pushing a 68-year-old with 15 years of diabetes from A1C 7.2% to 6.0% offers minimal microvascular benefit (the damage curve flattens below 7%) while adding cost, injection burden, and GI side effects. That's a reasonable position. The patient's preference and risk tolerance should drive the decision, not a one-size-fits-all target.

If your A1C is 7.1% on tirzepatide 10 mg and you feel good, stopping there is rational. If you want to push to 6.0% because you're 40 and planning another 50 years without retinopathy, that's also rational. Both are evidence-informed choices.

FAQ

How fast does Mounjaro lower blood sugar? Fasting glucose typically drops 20 to 30 mg/dL within the first week. A1C begins declining around week 4 but the steepest reduction occurs between weeks 12 and 20. Most patients reach their lowest A1C by week 24.

What is the average A1C reduction on Mounjaro? The average A1C reduction is 1.87% on 5 mg, 2.07% on 10 mg, and 2.46% on 15 mg after 40 weeks, based on SURPASS-1 trial data in treatment-naive patients with baseline A1C of 7.9%.

Does Mounjaro work better than Ozempic for blood sugar? In the SURPASS-2 head-to-head trial, tirzepatide 15 mg reduced A1C by 2.30% compared to 1.86% for semaglutide 1 mg. Tirzepatide produces about 0.4 percentage points more A1C reduction on average.

Can Mounjaro lower blood sugar too much? Hypoglycemia (blood sugar below 70 mg/dL) occurs in under 1% of patients on tirzepatide monotherapy. It becomes more common when combined with sulfonylureas or insulin. If you're experiencing frequent lows, contact your provider to adjust other diabetes medications.

How much does Mounjaro lower fasting glucose? Fasting plasma glucose drops by an average of 52 mg/dL on 5 mg, 62 mg/dL on 10 mg, and 68 mg/dL on 15 mg after 40 weeks. Most of the reduction happens in the first 12 weeks.

What percentage of people reach an A1C below 7% on Mounjaro? In SURPASS-1, 85% of patients on 5 mg, 92% on 10 mg, and 94% on 15 mg reached an A1C below 7% after 40 weeks. Starting A1C was 7.9%, so most patients were close to goal at baseline.

Does starting A1C affect how much Mounjaro lowers blood sugar? Yes. Patients with higher baseline A1C see larger absolute reductions. In SURPASS-4, patients starting above 9% saw A1C drops of 2.8 to 3.1%, while those starting below 8% saw drops of 1.6 to 1.9%.

How long does it take for A1C to drop on Mounjaro? A1C reflects a 90-day average, so the first measurable drop appears around week 12. The majority of A1C reduction occurs between weeks 12 and 24, with smaller continued declines through week 40.

Can you take Mounjaro if your A1C is already below 7%? Mounjaro is FDA-approved only for type 2 diabetes (A1C ≥6.5%) or weight management in patients with obesity. Using it for prediabetes (A1C 5.7 to 6.4%) is off-label. Some providers prescribe it off-label for weight loss in prediabetic patients, but insurance typically won't cover it.

Does Mounjaro lower postprandial blood sugar? Yes. Tirzepatide slows gastric emptying and enhances insulin secretion in response to meals. Postprandial glucose spikes typically decrease by 30 to 50 mg/dL within 8 weeks, based on CGM data patterns.

What should I do if my blood sugar isn't dropping on Mounjaro? If your A1C hasn't declined after 16 weeks, check fasting C-peptide to assess beta-cell function, review your carbohydrate intake, and audit other medications for glucose-raising effects. Consider testing for LADA if you're lean and under 40.

Is a 2-point A1C drop in 6 months realistic on Mounjaro? Yes, if you're on 10 mg or 15 mg and your starting A1C is above 8%. Patients starting at 7.5% typically see 1.5 to 1.8 point drops. The higher your baseline, the larger the absolute reduction.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
3. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
6. ElSayed NA et al. Standards of Care in Diabetes - 2023. Diabetes Care. 2023.
7. Gerstein HC et al. Effects of intensive glucose lowering in type 2 diabetes (ACCORD). New England Journal of Medicine. 2008.
8. American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
11. Frias JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, tirzepatide, in patients with type 2 diabetes. Diabetes Care. 2020.
12. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
13. Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015.
14. Khunti K et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, Obesity and Metabolism. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any brand-name pharmaceutical manufacturer.